PT-141 and Melanotan 2 are as directly related as two research peptides can be: PT-141 is a metabolite of Melanotan 2, formed by removing a single amidation from the parent molecule. That one change split the research history of the melanocortin peptides in two, sending one molecule toward an FDA approval and leaving the other as a research compound with an early-phase past. The chemistry of the split is small; its consequences were not.
The shared parent: alpha-MSH
Both compounds descend from alpha-melanocyte-stimulating hormone, the 13-residue hormone that activates melanocortin receptors. The natural hormone is fragile, so medicinal chemists at the University of Arizona in the 1980s built stabilised analogues around its active core. The workhorse result was Melanotan 2: a short cyclic peptide, closed by a lactam bridge, with a C-terminal amide. Cyclisation makes it resistant to degradation and potent at melanocortin receptors.
Melanocortin receptors come in subtypes with different jobs. MC1R, in skin, drives melanin synthesis; that is the pigmentation axis and the original research interest, photoprotection through induced tanning. MC4R, in the central nervous system, sits in circuits governing appetite and sexual arousal. Melanotan 2 activates both, which is exactly why its early human studies produced two storylines at once: Dorr and colleagues' 1996 pilot study documented tanning effects, and Wessells and colleagues reported in 2000 that the compound initiated erections in men with erectile dysfunction, an effect traced to central MC4R activation rather than anything vascular.
The metabolite that became a drug
During the Melanotan 2 studies, researchers characterised its circulating metabolites and found that the des-amide form, the same cyclic peptide with a carboxylic acid instead of the C-terminal amide, retained the central MC4R activity. That metabolite was developed separately under the name bremelanotide, and PT-141 was its development code.
The clinical programme concentrated on the MC4R storyline. After an intranasal formulation was abandoned over blood pressure findings, subcutaneous bremelanotide went through the two RECONNECT phase 3 trials in hypoactive sexual desire disorder in women, published by Kingsberg and colleagues in 2019, and won FDA approval that year under the brand name Vyleesi. Transient blood pressure elevation and nausea are the labelled effects a research reader will recognise from the trial data.
That gives PT-141 something rare in this catalogue: the research-grade compound has a pharmaceutical twin with a full modern regulatory dossier. The situation resembles SS-31 and elamipretide, and the same caution applies. The approved product and a research vial share a molecule, not a manufacturing standard or an authorised use.
What separates them in research terms
Receptor profile first. Both are potent MC4R agonists; Melanotan 2 carries the stronger pigmentation story because its use history and its MC1R activity made tanning the observed endpoint. PT-141's documented human record is concentrated on the central endpoint, and its pigmentation activity is comparatively incidental in the literature.
Evidence base second, and here the gap is wide. Melanotan 2's human record consists of small academic studies from the 1990s and 2000s; it was never developed to approval, and its market presence since has been unregulated, a fact regulators in several countries have publicised. PT-141's record runs through controlled phase 3 trials with published safety data. For a researcher deciding which literature to stand on, that difference matters more than the single chemical group that separates the molecules.
Format, finally. Both peptides appear in research in injectable and intranasal formats; our catalogue supplies the pair as PT-141 nasal spray and Melanotan 2 nasal spray, each batch verified by certificate of analysis. The intranasal route has its own history here, since it was an intranasal bremelanotide programme that surfaced the blood pressure findings, and route-specific results should never be transferred silently between formats.
The takeaway
Melanotan 2 is the stabilised parent, active at both the pigmentation and central melanocortin receptors, with an early-phase academic record and no approval. PT-141 is its des-amide metabolite, developed into bremelanotide with a genuine phase 3 dossier behind it. One chemical group and twenty years of divergent development separate them. Read tanning findings against Melanotan 2, read the controlled central-endpoint data against PT-141, and keep the two literatures straight, because the market frequently does not.
All products are intended for research use only. Not for human consumption. Must be 21 years of age or older to purchase.
References
1. Dorr, R. T., Lines, R., Levine, N., et al. (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences, 58(20), 1777-1784.
2. Wessells, H., Levine, N., Hadley, M. E., et al. (2000). Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with melanotan II. International Journal of Impotence Research, 12(Suppl 4), S74-S79.
3. Kingsberg, S. A., Clayton, A. H., Portman, D., et al. (2019). Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstetrics and Gynecology, 134(5), 899-908.
